Monoclonal antibody therapy of cancer (original) (raw)

• Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
  Article CAS PubMed Google Scholar
• Badger, C., Anasetti, C., Davis, J. & Berstein, I. Treatment of malignancy with unmodified antibody. Pathol. Immunopathol. Res. 6, 419–434 (1987).
  CAS PubMed Google Scholar
• Khazaeli, M.B., Conry, R.M. & LoBuglio, A.F. Human immune response to monoclonal antibodies. J. Immunother. 15, 42–52 (1994).
  CAS Google Scholar
• Lee, J., Fenton, B.M., Koch, C.J., Frelinger, J.G. & Lord, E.M. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 58, 1478–1485 (1998).
  CAS PubMed Google Scholar
• Miller, R.A., Maloney, D.G., Warnke, R. & Levy, R. Teatment of B-cell lymphoma with monoclonal anti-idiotype antibody. Medical Intelligence 306, 517–522 (1982).
  CAS Google Scholar
• McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833 (1998).
  CAS PubMed Google Scholar
• Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002).
  CAS PubMed Google Scholar
• Leonard, J.P. & Link, B.K. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. Oncol. 29, 81–86 (2002).
  CAS PubMed Google Scholar
• Witzig, T.E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 2453–2463 (2002).
  CAS PubMed Google Scholar
• Kaminski, M.S. et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96, 1259–1266 (2000).
  CAS PubMed Google Scholar
• Lundin, J. et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100, 768–773 (2002).
  CAS PubMed Google Scholar
• Sievers, E.L. et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93, 3678–3684 (1999).
  CAS PubMed Google Scholar
• Kreitman, R.J. et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345, 241–247 (2001).
  CAS PubMed Google Scholar
• Cobleigh, M.A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639–2648 (1999).
  CAS PubMed Google Scholar
• Vogel, C.L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
  CAS PubMed Google Scholar
• Slamon, D.J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  CAS PubMed Google Scholar
• Robert, F. et al. Phase I study of anti–epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 3234–3243 (2001).
  CAS PubMed Google Scholar
• Foon, K.A. et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58, 984–990 (2004).
  CAS PubMed Google Scholar
• Egen, J.G., Kuhns, M.S. & Allison, J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611–618 (2002).
  CAS PubMed Google Scholar
• Sanderson, K. et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23, 741–750 (2005).
  CAS PubMed Google Scholar
• Steplewski, Z., Lubeck, M.D. & Koprowski, H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221, 865–867 (1983).
  CAS PubMed Google Scholar
• Heijnen, I.A. & van de Winkel, J.G. Human IgG Fc receptors. Int. Rev. Immunol. 16, 29–55 (1997).
  CAS PubMed Google Scholar
• Sulica, A., Morel, P., Metes, D. & Herberman, R.B. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int. Rev. Immunol. 20, 371–414 (2001).
  CAS PubMed Google Scholar
• Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443–446 (2000).
  Article CAS PubMed Google Scholar
• Shields, R.L. et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276, 6591–6604 (2001).
  CAS PubMed Google Scholar
• Ghetie, V. & Ward, E.S. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol. 18, 739–766 (2000).
  CAS PubMed Google Scholar
• Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176–180 (1999).
  CAS PubMed Google Scholar
• Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99, 754–758 (2002).
  CAS PubMed Google Scholar
• Weng, W.K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940–3947 (2003).
  CAS PubMed Google Scholar
• Janeway, C. & Travers, P. Immunobiology, vol. 3 (Current Biology, London, 1997).
  Google Scholar
• Di Gaetano, N. et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171, 1581–1587 (2003).
  CAS PubMed Google Scholar
• Golay, J. et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383–3389 (2001).
  CAS PubMed Google Scholar
• Gelderman, K.A., Tomlinson, S., Ross, G.D. & Gorter, A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 25, 158–164 (2004).
  CAS PubMed Google Scholar
• Sunada, H., Magun, B.E., Mendelsohn, J. & MacLeod, C.L. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA 83, 3825–3829 (1986).
  CAS PubMed PubMed Central Google Scholar
• Li, S. et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7, 301–311 (2005).
  CAS PubMed Google Scholar
• Franklin, M.C. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317–328 (2004).
  CAS PubMed Google Scholar
• Arteaga, C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 29, 3–9 (2002).
  CAS PubMed Google Scholar
• Austin, C.D. et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 15, 5268–5282 (2004).
  CAS PubMed PubMed Central Google Scholar
• May, K.F.J., Chen, L., Zheng, P. & Liu, Y. Anti-4–1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62, 3459–3465 (2002).
  CAS PubMed Google Scholar
• Hirano, F.K.K. et al. Blockade of B7–H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089–1096 (2005).
  CAS PubMed Google Scholar
• Wu, A.M. & Senter, P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137–1146 (2005).
  CAS PubMed Google Scholar
• Gordon, L.I. et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma 5, 98–101 (2004).
  CAS PubMed Google Scholar
• Kaminski, M.S. et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352, 441–449 (2005).
  CAS PubMed Google Scholar
• Behr, T.M. et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94, 1373–1381 (2002).
  CAS PubMed Google Scholar
• Scott, A.M. et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin. Cancer Res. 11, 4810–4817 (2005).
  CAS PubMed Google Scholar
• Chong, G. et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin. Cancer Res. 11, 4818–4826 (2005).
  CAS PubMed Google Scholar
• Francis, R.J. et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer 87, 600–607 (2002).
  CAS PubMed PubMed Central Google Scholar
• Mayer, A. et al. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer 90, 2402–2410 (2004).
  CAS PubMed PubMed Central Google Scholar
• Cobleigh, M. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17, 2639–2648 (1999).
  CAS PubMed Google Scholar
• Baselga, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737–744 (1996).
  CAS PubMed Google Scholar
• Slamon, D. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  CAS PubMed Google Scholar
• Norton, L., Slamon, D. & Leyland-Jones, B. in Proceedings of the American Society of Clinical Oncology vol. 18, 127a (ASCO Publications, Alexandria, Virginia, USA, 1999).
  Google Scholar
• Baselga, J. Clinical trials of HerceptinR (trastuzumab). Eur. J. Cancer 37, S18–S24 (2001).
  CAS PubMed Google Scholar
• Pegram, M.D. et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2 positive advanced breast cancer. J. Natl. Cancer Inst. 96, A759–A769 (2004).
  Google Scholar
• Pegram, M. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185her2/neu monoclonal antibody plus cisplatin in patients with HER2/_neu_-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659–2671 (1998).
  CAS PubMed Google Scholar
• Miller, K.D. et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (suppl. 3) 15, S38–S40 (2001).
  Google Scholar
• Modjtahedi, H., Komurasaki, T., Toyoda, H. & Dean, C. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours. Int. J. Cancer 75, 310–316 (1998).
  CAS PubMed Google Scholar
• Teramoto, T., Onda, M., Tokunaga, A. & Asano, G. Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer 77, 1639–1645 (1996).
  CAS PubMed Google Scholar
• Arteaga, C.L., Coronado, E. & Osborne, C.K. Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol. Endocrinol. 2, 1064–1069 (1988).
  CAS PubMed Google Scholar
• Hoffmann, T., Hafner, D., Ballo, H., Haas, I. & Bier, H. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17, 4419–4425 (1997).
  CAS PubMed Google Scholar
• Fan, Z., Baselga, J., Masui, H. & Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53, 4637–4642 (1993).
  CAS PubMed Google Scholar
• Baselga, J. et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 85, 1327–1333 (1993).
  CAS PubMed Google Scholar
• Sunada, H., Yu, P., Peacock, J.S. & Mendelsohn, J. Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J. Cell. Physiol. 142, 284–292 (1990).
  CAS PubMed Google Scholar
• Fan, Z., Masui, H., Altas, I. & Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53, 4322–4328 (1993).
  CAS PubMed Google Scholar
• Baselga, J. et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904–914 (2000).
  CAS PubMed Google Scholar
• Saltz, L.B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004).
  CAS PubMed Google Scholar
• Starling, N. & Cunningham, D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr. Opin. Oncol. 16, 385–390 (2004).
  CAS PubMed Google Scholar
• Herbst, R. & Langer, C. Epidermal Growth Factor Receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 29, 27–36 (2002).
  CAS PubMed Google Scholar
• Mendez, M. et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146–156 (1997).
  CAS PubMed Google Scholar
• Yang, X. et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236–1243 (1999).
  CAS PubMed Google Scholar
• Vanhoefer, U. et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22, 175–184 (2004).
  CAS PubMed Google Scholar
• Johns, T.G. et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J. Biol. Chem. 279, 30375–30384 (2004).
  CAS PubMed Google Scholar
• Shankar, S. et al. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nucl. Med. Biol. 31, 909–919 (2004).
  CAS PubMed Google Scholar
• Haga, Y., Sivinski, C., Woo, D. & Tempero, M. Dose related comparison of antibody-dependent cellular cytotoxicity with chimeric and native monoclonal antibody 17–1A. Improved cytolysis of pancreatic cancer cells with chimeric 17–1A. Int. J. Pancreatol. 15, 43–50 (1994).
  CAS PubMed Google Scholar
• Meredith, R. & et al. Pharmacokinietics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1 17–1A monoclonal antibody. J. Nucl. Med. 32, 1162–1168 (1991).
  CAS PubMed Google Scholar
• Hartung, G. et al. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 28, 347–350 (2005).
  CAS PubMed Google Scholar
• Gold, P. & Freedman, S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 12 1, 439–462 (1965).
  Google Scholar
• Wong, J.Y.C. et al. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin. Cancer Res. 6, 3855–3863 (2000).
  CAS PubMed Google Scholar
• Juweid, M.E. et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J. Nucl. Med. 41, 93–103 (2000).
  CAS PubMed Google Scholar
• Mayer, A. et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res. 6, 1711–1719 (2000).
  CAS PubMed Google Scholar
• Pukac, L. et al. HGS ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 92, 1430–1441 (2005).
  CAS PubMed PubMed Central Google Scholar
• Loo, D. et al. The monoclonal antibody RAV12 induces oncotic cell death in vitro and exhibits potent anti-tumor activity in human tumor xenografts. Proc. Am. Assoc. Cancer Res. 46, 558 (2005).
  Google Scholar
• Nadler, L. et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40, 3147–3154 (1980).
  CAS PubMed Google Scholar
• Miller, R., Maloney, D., Warnke, R. & Levy, R. Treatment of B-cell lymphoma with monocolonal anti-idiotype antibody. N. Engl. J. Med. 306, 517–522 (1982).
  CAS PubMed Google Scholar
• Vuist, W., Levy, R. & Maloney, D. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83, 899–906 (1994).
  CAS PubMed Google Scholar
• Swisher, E. et al. Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 77, 1977–1982 (1991).
  CAS PubMed Google Scholar
• Bowen, A. et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol. 96, 617–619 (1997).
  CAS PubMed Google Scholar
• Lundin, J. et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J. Clin. Oncol. 16, 3257–3263 (1998).
  CAS PubMed Google Scholar
• Hale, G. et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92, 4581–4590 (1998).
  CAS PubMed Google Scholar
• Naparstek, E. et al. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Exp. Hematol. 27, 1210–1218 (1999).
  CAS PubMed Google Scholar
• Maloney, D. et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15, 3266–3274 (1997).
  CAS PubMed Google Scholar
• Maloney, D. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188–2195 (1997).
  CAS PubMed Google Scholar
• Shan, D., Ledbetter, J. & Press, O. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48, 673–683 (2000).
  CAS PubMed Google Scholar
• McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833 (1998).
  CAS PubMed Google Scholar
• Bernstein, N. et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9, 995–1001 (1988).
  Google Scholar
• Piro, L.D. et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10, 655–661 (1999).
  CAS PubMed Google Scholar
• Coiffier, B. et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92, 1927–1932 (1998).
  CAS PubMed Google Scholar
• Czuczman, M.S. et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17, 268–276 (1999).
  CAS PubMed Google Scholar
• Coiffier, B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin. Oncol. 29, 30–35 (2002).
  CAS PubMed Google Scholar
• Davis, T.A., Czerwinski, D.K. & Levy, R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5, 611–615 (1999).
  CAS PubMed Google Scholar
• Byrd, J. et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol. 17, 791–795 (1999).
  CAS PubMed Google Scholar
• Tai, Y.T. et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 64, 2846–2852 (2004).
  CAS PubMed Google Scholar
• Uckun, F.M. et al. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 76, 2449–2456 (1990).
  CAS PubMed Google Scholar
• Murphy, W.J. et al. Antibodies to CD40 prevent Epstein- Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood 86, 1946–1953 (1995).
  CAS PubMed Google Scholar
• Francisco, J.A. et al. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood 89, 4493–4500 (1997).
  CAS PubMed Google Scholar
• Funakoshi, S., Longo, D.L. & Murphy, W.J. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J. Immunother. Emphasis Tumor Immunol. 19, 93–101 (1996).
  CAS PubMed Google Scholar
• van Mierlo, G.J. et al. CD40 stimulation leads to effective therapy of CD40(+) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 99, 5561–5566 (2002).
  CAS PubMed PubMed Central Google Scholar
• Czuczman, M.S. et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 23, 4390–4398 (2005).
  CAS PubMed Google Scholar
• Leonard, J.P. et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res. 10, 5327–5334 (2004).
  CAS PubMed Google Scholar
• Leonard, J.P. et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 21, 3051–3059 (2003).
  CAS PubMed Google Scholar
• Cheng, J.D. et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol. Cancer Ther. 4, 351–360 (2005).
  CAS PubMed Google Scholar
• Scott, A.M. et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9, 1639–1647 (2003).
  CAS Google Scholar
• Garin-Chesa, P., Old, L.J. & Rettig, W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 87, 7235–7239 (1990).
  CAS PubMed PubMed Central Google Scholar
• Reardon, D.A. et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389–1397 (2002).
  CAS PubMed Google Scholar
• Rizzieri, D.A. et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 104, 642–648 (2004).
  CAS PubMed Google Scholar
• Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629–635 (2004).
  CAS PubMed Google Scholar
• Santimaria, M. et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9, 571–579 (2003).
  CAS PubMed Google Scholar
• Chang, S.S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).
  CAS PubMed Google Scholar
• Gordon, M. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843–850 (2001).
  CAS PubMed Google Scholar
• Kabbinavar, F.F. et al. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. J. Clin. Oncol. 23, 3697–3705 (2005).
  CAS PubMed Google Scholar
• Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
  CAS PubMed Google Scholar
• Willett, C.G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145–147 (2004).
  CAS PubMed PubMed Central Google Scholar
• Miller, K.D. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792–799 (2005).
  CAS PubMed Google Scholar
• Zhu, Z. et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17, 604–611 (2003).
  CAS PubMed Google Scholar
• Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553–563 (2004).
  CAS PubMed Google Scholar
• Lin, M.I. & Sessa, W.C. Antiangiogenic therapy: creating a unique “window” of opportunity. Cancer Cell 6, 529–531 (2004).
  CAS PubMed Google Scholar
• Gutheil, J.C. et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin. Cancer Res. 6, 3056–3061 (2000).
  CAS PubMed Google Scholar
• Byrd, J.C. et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol. 17, 791–795 (1999).
  CAS PubMed Google Scholar